Medicinal Chemistry and Chemical Biology

Group Site: 
Group Leader: 

Paul Brennan

Group Info

Research Areas

 

Epigenetic Chemical Probes

 

Epigenetics is the study of heritable changes to an organism that affect gene expression.  With the discovery that histones can be extensively post-transnationally modified to alter the expression of the genes, it has been postulated that the combination of histone marks, especially lysine acetylation and methylation, constitutes an epigenetic code that is responsible for gene regulation in normal cell differentiation and in disease progression.  In order to decipher the epigenetic code, the Structural Genomics Consortium has embarked on a program to discover thirty-seven selective chemical probes that inhibit the major families of histone modifying enzymes. 

 

Histone

Modification

Write

Read

Erase


Acetyl

HAT

Bromodomain

HDAC


Methyl

HMT

Tudor Domain

Chromodomain

PHD Domain

HDM

HAT: histone acetyl transferase; HDAC: histone deacetylase; HMT: histone methyl transferase; HDM: histone demethylase.

In Oxford, the focus is on bromodomains: protein recognition domains which bind acetylated lysine and histone demethylases: enzymes which remove methyl groups from the terminal amine of histone lysine residues.  The chemical probe projects begin with screening commercial and collaborator compound collections to identify hit compounds.  Through an iterative medicinal chemistry process of x-ray crystallography, medicinal chemistry compound design, organic synthesis and screening the hit compounds are optimized for potency, selectivity and cell activity.  Members of the SGC medicinal chemistry team gain expertise in structure-based drug design, in silico compound docking, structure-activity relationship analysis and modern organic synthesis.

Group Members
Paul Brennan

Paul Brennan received his PhD in organic chemistry from the University of California, Berkeley under the mentorship of Paul Bartlett working on synthetic methodology for combinatorial chemistry and synthesizing inhibitors for new novel anti-bacterial targets.  Following three years of post-doctoral research with Steve Ley in Cambridge University on the total synthesis of rapamycin, Paul returned to California to take a position at Amgen.  His research was focussed on designing and synthesizing kinase inhibitors for oncology.  After two years at Amgen, Paul accepted a position as medicinal chemistry design lead at the world-renowned Pfizer labs in Sandwich, UK.  Over the next six years Paul designed and synthesized compounds for most major drug classes: GPCR’s, CNS-targets, ion-channels and metabolic enzymes.  Following the closure of the Pfizer site in Sandwich, Paul joined the Structural Genomics Consortium as the principal investigator for medicinal chemistry to discover chemical probes for epigenetic proteins.

Contact

paul [dot] brennan[at]sgc [dot] ox [dot] ac [dot] uk (Dr. Paul Brennan)

SGC
University of Oxford
Old Road Campus REsearch Building
Roosevelt Drive
Headington
Oxford
OX3 7DQ
UK

Phone: +44 1865 617574